G protein-coupled receptors (GPCRs) can assume multiple conformations and possess multiple binding sites. Whereas endogenous agonists acting at the orthosteric binding site stabilize the active receptor conformation, small molecules that act at nonorthosteric sites can stabilize alternative conformations. The large majority of these allosteric modulators associate with extracellular loops of GPCRs. The role of intracellular domains in mediating allosteric modulation is largely unknown. In screening a small-molecule library for inhibitors of platelet activation, we identified a family of compounds that modified PAR1-mediated granule secretion. The most potent inhibitory compound, termed JF5, also demonstrated noncompetitive inhibition of the α 2A -adrenergic receptor. Aggregation studies using a battery of platelet GPCR agonists demonstrated that sensitivity to JF5 was limited to GPCRs that possessed a constrained eighth helix, as defined by a C-terminal palmitoylation site and interactions with TM7 and the i1 loop. Inhibition by JF5 was overcome in a PAR1 mutant in which the eighth helix was deleted, confirming a role for helix 8 in JF5 activity. Evaluation of downstream signaling showed that JF5 was selective with regard to G protein coupling, blocking signaling mediated by G αq but not G α12 . The compound inhibited thrombus formation in vivo following vascular injury with an IC 50 of ∼1 mg/kg. These results indicate a role for helix 8 in conferring sensitivity to small molecules, and show that this sensitivity can be exploited to control platelet activation during thrombus formation.
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thrombosis | chemical genetics | thrombin receptor | platelet signaling A single G protein-coupled receptor (GPCR) can assume multiple conformations, differentially mediate distinct signaling pathways, and interact with adjacent GPCRs and other proteins to achieve a range of activation states (1) . These conformations and signaling properties can be influenced not only by small molecules that act at the ligand binding pocket, but also by allosteric modulators that act outside of the ligand-binding pocket and stabilize alternative conformations (2) . Allosteric modulators of GPCRs most often act at extracellular sites. Many of these sites are located in the second and third extracellular loops, as well as at the top of TM7 (2) . Emerging studies indicate that allosteric modulation by GPCR antagonists may occur at the intracellular face of GPCRs (3) (4) (5) (6) . Small-molecule inhibitors of chemokine receptors that act at sites on the cytoplasmic tail of CCR4 and CXCR2 have been identified (3) (4) (5) . The possibility that nonchemokine GPCRs can be modulated in an analogous manner has been proposed, but has not been formally explored.
Potential advantages of allosteric modulators, such as an improved therapeutic window and increased selectivity, have been proposed, and a few allosteric modulators of GPCR function are used as therapeutics (2) . However, the majority of GPCR antagonists used in clinical practice are orthosteric inhibitors. Although affinity-based approaches such as radioligand binding studies efficiently identify orthosteric inhibitors of GPCR function, they are not well-suited to identify nonorthosteric antagonists. Use of cell-based or physiological assays is typically required for identification of such compounds.
The platelet is a useful biological system for evaluating GPCR function (7) . It is a highly specialized cell that surveys the circulatory system for breeches of vascular integrity. Accordingly, the platelet possesses a wide repertoire of GPCRs to recognize multiple inputs such as activation of the coagulation system, factors released by adjacent platelets, adrenergic tone, complement activation, and signals from endothelial and inflammatory cells. In maintaining hemostasis, the platelet undergoes a profound response to agonist stimulation. The rapid and robust change from a quiescent to an activated state produces a favorable signal-to-noise ratio in functional assays. Availability of large quantities of platelets through blood banks enables ex vivo highthroughput screening, increasing the likelihood of identifying physiologically active compounds. In addition, platelets are important therapeutic targets. Platelet-mediated arterial thrombosis, which can cause myocardial and cerebral infarction, is the leading cause of morbidity and mortality in the industrialized world.
To identify biological probes that modulate PAR1-mediated platelet signal transduction, we have screened a 16,320-compound library and used counterscreening assays to identify and characterize active compounds. A family of small molecules was discovered that included both inhibitory and augmenting compounds. The most potent inhibitory member of this family, termed JF5, blocked activation through a discrete subset of GPCRs that contained a constrained eighth helix (H8). The compound was inhibitory in an in vivo model of thrombus formation. These studies demonstrate the feasibility of targeting intracellular domains of GPCRs using small molecules to inhibit platelet signaling cascades during thrombus formation.
Results
Identification of a Family of Small Molecules that Target PAR1.
We used a luciferin-luciferase-based assay to screen a 16,320-compound library to identify small molecules that inhibit platelet granule secretion induced by the PAR1 agonist, SFLLRN (Fig.  1A) . Primary screening identified 1,2,3,4-tetrahydro-4-pentyl-9H-cyclopenta[b]quinolin-9-imine (compound 5-C; Fig. S1 ) along with two analogs (compounds 3-C and 4-C; Fig. S1 ) as inhibitors of PAR1-mediated dense granule release. Evaluation of structure-activity relationships of these compounds revealed a family of compounds that are capable of either inhibiting or augmenting SFLLRN-induced platelet activation, depending on the length of their alkyl tails (Fig. 1B) . Compounds with alkyl tails of three to five carbons inhibited SFLLRN-induced platelet activation. Potency of inhibition increased as the length of the tail increased from three to five carbons (Fig. S1 ). Analogs with alkyl tails of seven to 16 carbons did not inhibit, but instead augmented activation of platelets by submaximal concentrations of SFLLRN (Fig. 1B) . Breaking the cyclopenta ring failed to abrogate the inhibitory activity of the compound (Fig. S1) . These results define a family of alkylated quinolines capable of modulating PAR1-mediated platelet activation and demonstrate the importance of the alkyl tail in the activity of these compounds.
The most potent inhibitory member of this family of compounds, termed JF5, the analog with the five-carbon tail, inhibited SFLLRN-induced α-granule secretion with an IC 50 of 4 μM ( Fig. 2A) . To further assess the selectivity of JF5, we determined whether it inhibited platelet activation induced by agonists other than SFLLRN. At concentrations that completely abolished SFLLRN-induced platelet α-granule secretion, JF5 failed to inhibit α-granule secretion induced by the GPVI agonist convulxin, the PKC activator PMA, or the Ca 2+ ionophore A23187 ( Fig. 2A) . Platelet activation induced by the PAR4 agonist AYPGKF was also unaffected by JF5 ( Fig. 2A and Fig. S2 ). These results suggested that JF5 targeted proximal steps in the PAR1 signaling pathway. To evaluate whether JF5 inhibited PAR1 coupling to G α subunits, we determined its effect in GTP [γ-
35 S] binding and GTPase activity assays. JF5 inhibited both SFLLRN-induced GTP[γ-
35 S] binding and GTPase activity in platelet membranes (Fig. 2B) . In contrast, JF5 failed to affect GTPase activity mediated by U46619 even at 1 mM JF5. To determine whether JF5 inhibited heterotrimeric G proteins or downstream effectors, we tested the ability of JF5 to inhibit GTPγS-mediated platelet activation in permeabilized platelets (Fig. 2C) . JF5 inhibited SFLLRN-induced, but not GTPγS-induced, platelet activation in this system. These results suggest that JF5 acts directly on PAR1.
Helix 8 of Susceptible GPCRs Confers Sensitivity to JF5. In further studies to define the specificity of JF5, we found that signaling through the α 2A -adrenergic receptor also demonstrated sensitivity. Platelet aggregation induced by epinephrine plus a substimulatory concentration of U46619, used to provide supplemental G αq signaling, was inhibited by JF5 in a dose-dependent manner (Fig. 3A) . Yohimbine inhibited aggregation under these conditions, confirming the dependence on epinephrine. Aggregation induced by epinephrine plus a substimulatory concentration of arginine vasopressin (AVP) or AYPGKF was also inhibited by JF5. In contrast, JF5 failed to inhibit platelet aggregation induced by ADP (Fig. 3A) . To confirm that the compound inhibits the α 2A -adrenergic receptor and to determine the mode of inhibition, we evaluated the ability of JF5 to interfere with the binding of [ (Fig. 3B ). In contrast, the β max was not significantly changed. These results demonstrate that JF5 interacts with the α 2A -adrenergic receptor as well as on PAR1.
To determine whether other platelet GPCRs are sensitive to JF5, we tested the ability of the compound to inhibit aggregation induced by several agonists that stimulate platelet GPCRs. JF5 inhibited platelet aggregation induced through PAR1, the 5-HT 2A receptor, and CCR4 (Fig. 4A ). In contrast, JF5 failed to inhibit aggregation mediated through PAR4, the thromboxane A 2 (TP) receptor, or VP1a ( . Permeabilized platelets were subsequently exposed to buffer alone (NA), 100 μM SFLLRN, or 50 μM GTPγS, and assayed for P-selectin expression by flow cytometry (n = 3 ± SD).
compared with the receptors that were resistant to JF5. However, analysis of the primary sequence of the cytoplasmic tails of these receptors revealed differences in the eighth helix (H8). GPCRs that were sensitive to JF5 contained features previously predicted to constrain H8 (Fig. 4B) (8, 9) . Several of these features are observed in PAR1, including two palmitoylation sites at the C-terminal end of H8 (Fig. 4C, indicated in red) , an 8-1 ionic interaction between E377 and K135 (Fig. 4C, Inset) , and a 7-8 Hbond network between the carbonyl oxygen of Y372 on TM7 and the Q379-R380 dyad on H8 (Fig. 4C, Inset) . In addition, sensitive GPCRs were devoid of amino acids that tend to decrease or disrupt α-helix propensity (Fig. 4B, indicated in blue) . GPCRs that were not sensitive to the compound possessed a maximum of one feature and possessed amino acids that tend to disrupt helices. These observations implicate H8 in the inhibitory activity of JF5.
To assess the hypothesis that H8 contributes to the inhibitory activity of JF5, the compound was evaluated for its ability to inhibit IP 3 generation in COS7 cells overexpressing WT PAR1 or a PAR1 mutant in which residues 376-386 had been replaced with three alanine residues (ΔH8 PAR1). JF5 abolished SFLLRNinduced IP 3 generation in COS7 cells expressing WT PAR1 (Fig.  4D ). COS7 cells expressing ΔH8 PAR1 demonstrated decreased responsiveness in this assay, but retained the ability to respond to SFLLRN. Loss of H8 largely reversed inhibition by JF5 such that 10 μM SFLLRN elicited IP 3 generation equally in the absence or presence of JF5 (Fig. 4D) . A downward shift of the dose-response following JF5 incubation in transfected COS7 cells was observed and may represent an inhibitory effect of JF5 on constitutive IP 3 production mediated by endogenous PAR1. To evaluate whether JF5 acts through thiol modification, as has been described for other inhibitors of GPCRs (10) (11) (12) , the effect of DTT on JF5 activity was evaluated. Incubation of JF5 with DTT failed to block its inhibitory activity (Fig. S3A) . In addition, inhibition by JF5 was reversible (Fig. S3B) . Confirmatory studies demonstrated that agonist-stimulated Ca 2+ flux in cultured cells transfected with PAR1, but not those transfected with the TP receptor, P2Y 1 , or the EP1 receptor, was sensitive to JF5 (Fig. S3C) . Selective Inhibition of G α Subunits by JF5. H8 functions directly in coupling to G α subunits. A nonorthosteric antagonist the activity of which is conferred through H8 could demonstrate selectivity at the level of G protein coupling. Inspection of aggregometry tracings of platelets stimulated through PAR1 in the presence of JF5 demonstrated that, although JF5 inhibited platelet aggregation, it failed to inhibit platelet shape change (Fig. S4A) , which is mediated by G α12/13 . In contrast, SFLLRN-induced shape change was inhibited by SCH79797, an orthosteric inhibitor of PAR1. Shape change in the presence of JF5 was sensitive to the Rho kinase inhibitor, Y-27632, indicating involvement of Rho kinase in JF5-resistant shape change. These results suggest that JF5 fails to inhibit signaling downstream of G α12/13 . To further evaluate this premise, we determined the effect of JF5 on SFLLRN-induced G α12 -dependent decreased barrier function by measuring changes in transepithelial resistance (TER) in MDCK cells overexpressing G α12 . Stimulation of these cells with SFLLRN resulted in a decrease in TER at 2 h compared with untreated cells (Fig. S4B , P < 0.01). Cells exposed to JF5 before stimulation with SFLLRN-induced also demonstrated a decrease in TER compared with untreated cells (Fig. S4B , P < 0.04). JF5 at concentrations of up to 200 μM had no effect on either baseline TER or decrease in TER following stimulation with SFLLRN (Fig. 5) . In contrast, SCH79797 inhibited SFLLRNinduced decrease in TER at 1 μM. These observations show that JF5 fails to inhibit signaling through G α12 .
JF5 Inhibits Thrombus Formation in Vivo.
To determine whether JF5 interferes with platelet activation during thrombus formation, we evaluated the effect of JF5 on platelet accumulation following laser-induced arteriolar injury in mice. When infused into mice, JF5 was well tolerated at 6 mg/kg delivered as a bolus followed by a constant infusion. The compound nearly abolished accumulation of platelets into thrombi (Fig. 6A) . JF5 inhibited by up to 80% (P < 0.05) the amount of platelets remaining at the injury site 5 min after laser-induced vascular injury. Evaluation of dose dependency demonstrated that JF5 inhibited thrombus formation after vascular injury with an IC 50 of ∼1 mg/kg (Fig. 6B ). JF5 also delayed platelet accumulation at the site of vascular injury. Kinetic studies demonstrated that the time to 50% maximal platelet accumulation was increased more than twofold (P < 0.001) after infusion of 1 mg/kg JF5. These results demonstrate that JF5 is a potent antithrombotic agent. Thrombin is an important mediator of platelet activation during thrombus formation after laser-induced injury (13) . In mice, thrombin stimulates platelets through activation of PAR4 (14) . However, the human PAR4 receptor is resistant to inhibition by JF5 (Fig. 4A) . We therefore assessed the ability of JF5 to inhibit activation of murine platelets stimulated through PAR4. JF5 inhibited AYPGKF-mediated activation of murine platelets with an IC 50 of ∼10 μM (Fig. 6C and Fig. S5 ). Unlike human PAR4, murine PAR4 possesses a cytoplasmic tail that contains Cys 368 at the C-terminal end of H8 and is devoid of glycine, which can disrupt α-helices (Fig. 6C ). These observations further support the premise that JF5 affects platelet activation stimulated through GPCRs containing a constrained H8.
Discussion
Although most known GPCR allosteric binding sites have been identified on the extracellular surface of GPCRs, some sites have been proposed to reside on the intracellular face. Evidence for intracellular allosteric binding sites has been demonstrated for chemokine receptors. Domain-swapping studies between CCR4 and CCR5 demonstrated that inhibition of signal transduction by a series of pyrazinyl-sulfonamides is conferred through the CCR4 C-terminal domain (3). Nicholls et al. have performed domainswapping studies with CXCR1 and CXCR2 and demonstrated that sensitivity to two nonpeptide CXCR2 antagonists is conferred by the C-terminal domain. Mutational analysis identified Lys 320 at the N terminus of H8 of CXCR2 as critical for binding the antagonists (4) . The mechanism of inhibition of CXCR2 by SB265610, Pteridone-1, and SCH527123 has also been evaluated by mutational analysis. These studies implicated the intracellular face of CXCR2 in binding all three antagonists and demonstrated the importance of Lys 320 for the binding of these compounds (5). The CCR4 and CXCR2 antagonists demonstrate the potential of targeting the intracellular face of GPCRs using small molecules to modulate chemokine receptor activity.
We have now characterized JF5 as a nonorthosteric antagonist of PAR1 the activity of which is conferred through H8. JF5 interferes with GPCRs stimulated by structurally diverse ligands that lack substantial homology among their extracellular domains. Competition binding measurements using the α 2A -adrenergic receptor inverse agonist [ at H8. Evaluation of JF5 in cells expressing either WT PAR1 or a ΔH8 PAR1 mutant confirms a role for H8 in JF5 activity. Although definitive localization of the binding site of JF5 on PAR1 will require X-ray crystallography or NMR, our study findings indicate that H8 confers sensitivity to JF5.
H8 typically forms an amphiphilic helix with hydrophobic residues oriented toward the inner leaflet of plasma membrane and hydrophilic residues facing outward (Fig. S6) (15) . Mutagenesis studies have defined functional significance for specific residues on both faces. Common interactions include a predicted ionic interaction between position 1 of H8 and the il loop, H-bond formation between position 3 of H8 and TM7, and a hydrophobic interaction between the tyrosine of the NPxxY motif and an aromatic amino acid at position 2 of H8 (8) . A palmitoylation site at the C terminus of H8 within many GPCRs is also known to influence H8 function. A combination of three of these features appears to be necessary to confer sensitivity to JF5. GPCRs that are resistant to JF5 lack two or more of these features and often contain prolines or glycines capable of destabilizing the α-helix (Fig. S6 ). This analysis demonstrates that GPCRs outside the ligand class of the screened receptor must be evaluated in assessing the selectivity and mechanism of action of an allosteric modulator, as structural homologies or key interactions may exist between ligand classes that do not exist within the class.
Studies performed using a model of laser-induced arteriolar thrombus formation demonstrate that JF5 is a potent antithrombotic (Fig. 6 ). This observation is consistent with the fact that JF5 blocks mPAR4, which is essential for thrombus formation in this model (13) . The α 2A -adrenergic and 5-HT 2A receptors are also blocked by JF5 and function in platelet-mediated thrombus formation (16) . Combination antiplatelet therapy is the standard of care for many coronary syndromes and additional reagents added to clopidogrel and aspirin may provide additional benefit (17) . JF5 demonstrates selectivity for G α subunits, blocking signaling through G αq but not G α12 (Fig. 5) . Whether inhibition of a subset of GPCRs and G protein signaling pathways by a single agent represents a viable strategy for antiplatelet therapy merits further study. JF5 will serve as a useful probe to evaluate the role of H8 in coupling of GPCRs to cognate G α subunits. Determination of the structural basis of JF5 activity will improve our understanding of how multiple conformations of GPCRs mediate signal transduction through different downstream effectors.
Materials and Methods
Materials. GTP[γ- High-Throughput Screening. A 16,320-compound library of drug-like synthetic small molecules designed to cover maximum pharmacophore diversity with a minimal number of compounds (DIVERSet, Chembridge) was screened at the Institute for Chemistry and Cell Biology. For this assay, 20 μL/well of platelet rich plasma obtained from the Beth Israel Deaconess Medical Center Blood Bank was added to 384-well plates. Compounds (100 nL in DMSO) were transferred to wells containing platelet-rich plasma using a D-TRAN XM3106-31 PN 4-axis cartesian robot (Seiko Instruments). After a 30-min incubation, 10 μL SFLLR (final concentration 100 μM) and 3 mg/mL luciferinluciferase were added to each well. Luminescence was then measured using a Tundra high-density imaging system (Imaging Research). The assay demonstrated a Z′ factor of 0.78 and a coefficient of variation of 7.2%. A platelet-free counterscreen was performed to exclude compounds that inhibited luciferase directly. In the platelet-free assay, compounds (100 nL) were added to wells containing 20 μL adenosine triphosphate 0.4 mM ATP. Luciferin-luciferase (0.15 mg/mL) was then added to the wells, and luminescence was measured. Compounds that significantly inhibited ATPinduced luminescence were not considered for further characterization as inhibitors of platelet secretion. P-Selectin Expression Assay. Platelet activation was measured by P-selectin surface expression using PE-antihuman P-selectin (BD) and flow cytometry (18) . Platelets were exposed to 1 μM streptolysin-O (MBL International) for studies using permeabilized platelets. Platelet activation is expressed as percentage of P-selectin surface expression compared with stimulated control.
Platelet Aggregation. Aggregation of platelet-rich plasma or washed platelets was initiated by the indicated concentrations of agonists and measured using a ChronoLog 680 Aggregation System) as described previously (19) . Experiments using epinephrine were performed in the presence of 50 U/mL hirudin to prevent thrombin formation.
GTPase and GTP[γ-
35 S] Binding Assays. Platelet membranes were prepared from platelets washed three times and subjected to sonication. After removal of intact cells by low speed centrifugation, membranes were pelleted at 50,000g, resuspended in ligand binding buffer, and flash frozen at −80°C. GTPase assays were performed by incubation of membranes with 4 μCi GTP[γ-32 P], 0.1 mM ATP, 5 mM phosphocreatine, and 1.2 mg/mL creatine phosphokinase as previously described (20) . Samples were incubated in the presence or absence of the indicated agonist for 10 min. The reaction was stopped with ice cold activated charcoal in phosphoric acid and samples pelleted. Radioactivity in the supernatant of the samples was analyzed by scintillation counting. GTP[γ- 35 S] binding to 4 μg/mL platelet membranes was induced using 20 μM SFLLRN and measured as previously described (21) , except that a final concentration of 1 μM GDP and 5 mM MgCl 2 was used in the assay buffer. Phosphoinositide Production Assay. SFLLRN-induced phosphoinositide levels were assayed as previously described (8) . COS7 fibroblasts expressing PAR1 or ΔH8 PAR1 mutants were incubated with [ 3 H]myoinositol. Cells were subsequently exposed to 10 μM JF5 for 15 min and stimulated with the indicated concentrations of SFLLRN for 30 min. To measure IP 3 generation, cells were extracted with cold methanol and chloroform. The extracts were loaded onto columns containing 1 mL anion exchange resin AG1 × 8, formate form, 100-200 mesh size, (Bio-Rad) and washed. Column fractions were eluted with 4 mL of 2 M ammonium formate/0.1 M formic acid into vials containing 7.5 mL scintillation mixture and then counted. The mean of two to four determinations was expressed as the fold stimulation above vehicle-treated cells.
Transepithelial Resistance. MDCK cells with inducible expression of WT G α12 (Tet-off) as previously described (23) Thrombus Formation Model. Thrombus formation following laser-induced injury of cremaster arterioles was visualized in 6-to 8-week-old C57BL/6 male mice by intravital microscopy as previously described (18) . Injury was induced by applying a pulsed nitrogen dye laser at 440 nm through the microscope objective using the Micropoint laser system (Photonics Instruments). Platelet accumulation to the thrombi following laser ablation was recorded continuously for 5 min using digital videomicroscopy, and total thrombus fluorescence in each frame of the videos was analyzed using Slidebook software (Intelligent Imaging Innovations). All procedures were approved by the Animal Care and Use Committee of the Beth Israel Deaconess Medical Center.
